Immunovant Current Cash

Immunovant posts a current cash of $900M as of March 2026. That compares with $710M in the prior-year period — up 26.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Immunovant's current cash was $710M. The latest reading is $900M — a 26.4% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of Immunovant's financial statement story. At $900M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for IMVT's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Immunovant's other metric pages and overview cover the third.

Judging Immunovant against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current cash easier to interpret. Start with $900M here, then scan peer and history charts to see if the gap is persistent.